Pfizer Hits A High Note
Stocks: (PFE)
Shares in Pfizer managed to hit their highest price since mid-2005. The shares hit $27.75 during trading after nearly touching $20 in November.
For the last four quarters, Pfizer’s financial results have been relatively strong, but somewhat mixed. In the quarter ending July 2, revenue was $10.8 billion. That number was stronger in each of the previous three quarters, but at $3.2 billion, operating income made for a better comparison with previous periods.
A jury also recently found that Pfizer did not infringe on a Synthon patent covering high blood pressure medication.
Pfizer is not without problems. Patent protection for its best-selling drug Lipitor will expire soon, and cholesterol generics are already in the market. According to the Associated Press, Pfizer’s soon-to-be released diabetes drug has just had a portion of its underlying intellectual property challenged. But, Pfizer has drugs that will be launched soon for people who want to stop smoking and a new inhaled insulin drug.
But, a lot of the rise in Pfizer’s stock is based on the intangible of having a new CEO whose predecessor was viewed as a failure. Hope springs eternal in the stock market, and Pfizer is not exception.
Investors can watch from the stadium seating and see how the new management does. Since Pfizer has a 3.5% yield, the presence of their coupons can warm them if Pfizer’s stock gets a little cool again.
Douglas A. McIntyre can be reached at douglasamcintyre@gmail.com. He does not own securities in companies that he writes about.
Shares in Pfizer managed to hit their highest price since mid-2005. The shares hit $27.75 during trading after nearly touching $20 in November.
For the last four quarters, Pfizer’s financial results have been relatively strong, but somewhat mixed. In the quarter ending July 2, revenue was $10.8 billion. That number was stronger in each of the previous three quarters, but at $3.2 billion, operating income made for a better comparison with previous periods.
A jury also recently found that Pfizer did not infringe on a Synthon patent covering high blood pressure medication.
Pfizer is not without problems. Patent protection for its best-selling drug Lipitor will expire soon, and cholesterol generics are already in the market. According to the Associated Press, Pfizer’s soon-to-be released diabetes drug has just had a portion of its underlying intellectual property challenged. But, Pfizer has drugs that will be launched soon for people who want to stop smoking and a new inhaled insulin drug.
But, a lot of the rise in Pfizer’s stock is based on the intangible of having a new CEO whose predecessor was viewed as a failure. Hope springs eternal in the stock market, and Pfizer is not exception.
Investors can watch from the stadium seating and see how the new management does. Since Pfizer has a 3.5% yield, the presence of their coupons can warm them if Pfizer’s stock gets a little cool again.
Douglas A. McIntyre can be reached at douglasamcintyre@gmail.com. He does not own securities in companies that he writes about.
posted by douglas mcintyre at 5:02 AM
Subscribe
<< Home